As next-generation promising medicines with specific targeting ability in immunotherapy, antibody-drug conjugates are expected to have high potential and wide applications in treating various types of cancer, fungal or bacterial infections, cardiovascular disorders, and immune diseases.
Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.
https://www.creative-biolabs.com/adc/services.htm
